製品の概要

  • 製品名
    Anti-Nmnat1 antibody [2642C5a]
    Nmnat1 一次抗体 製品一覧
  • 製品の詳細
    Mouse monoclonal [2642C5a] to Nmnat1
  • アプリケーション
    適用あり: Dot blot, WBmore details
  • 種交差性
    交差種: Recombinant fragment
    交差が予測される動物種: Human
  • 免疫原

    Recombinant fragment: TVVKGIISPV GDAYKKKGLI PAYHRVIMAE LATKNSKWVE VDTWESLQKE WKETLKVLRH HQEKLEASDC DHQQNSPTLE RPGRKRKWTE TQDSSQKKSL EPKTKAVP, corresponding to internal sequence amino acids 42-149 of Human Nmnat1

製品の特性

アプリケーション

Our Abpromise guarantee covers the use of ab84855 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
Dot blot Use at an assay dependent dilution.
WB Use at an assay dependent dilution. Predicted molecular weight: 32 kDa.

ターゲット情報

  • 機能
    Catalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP (PubMed:17402747). Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency (PubMed:17402747). Can use triazofurin monophosphate (TrMP) as substrate (PubMed:17402747). Also catalyzes the reverse reaction, i.e. the pyrophosphorolytic cleavage of NAD(+) (PubMed:17402747). For the pyrophosphorolytic activity, prefers NAD(+) and NaAD as substrates and degrades NADH, nicotinic acid adenine dinucleotide phosphate (NHD) and nicotinamide guanine dinucleotide (NGD) less effectively (PubMed:17402747). Involved in the synthesis of ATP in the nucleus, together with PARP1, PARG and NUDT5 (PubMed:27257257). Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming (PubMed:27257257). Fails to cleave phosphorylated dinucleotides NADP(+), NADPH and NaADP(+) (PubMed:17402747). Protects against axonal degeneration following mechanical or toxic insults.
  • 組織特異性
    Widely expressed with highest levels in skeletal muscle, heart and kidney. Also expressed in the liver pancreas and placenta. Widely expressed throughout the brain.
  • パスウェイ
    Cofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from nicotinamide D-ribonucleotide: step 1/1.
    Cofactor biosynthesis; NAD(+) biosynthesis; deamido-NAD(+) from nicotinate D-ribonucleotide: step 1/1.
  • 関連疾患
    Leber congenital amaurosis 9
  • 配列類似性
    Belongs to the eukaryotic NMN adenylyltransferase family.
  • 細胞内局在
    Nucleus.
  • Information by UniProt
  • 参照データベース
  • 別名
    • EC 2.7.7.1 antibody
    • LCA9 antibody
    • Leber's congenital amaurosis 9 antibody
    • NaMN adenylyltransferase 1 antibody
    • nicotinamide nucleotide adenylyltransferase 1 antibody
    • Nicotinamide-nucleotide adenylyltransferase 1 antibody
    • Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 antibody
    • nicotinate nucleotide adenylyltransferase 1 antibody
    • Nicotinate-nucleotide adenylyltransferase 1 antibody
    • NMN adenylyltransferase 1 antibody
    • NMN/NaMN adenylyltransferase 1 antibody
    • NMNA1_HUMAN antibody
    • Nmnat 1 antibody
    • Nmnat1 antibody
    • OTTHUMP00000001731 antibody
    • OTTHUMP00000001732 antibody
    • OTTHUMP00000035892 antibody
    • PNAT 1 antibody
    • PNAT1 antibody
    • pyridine nucleotide adenylyltransferase 1 antibody
    see all

画像

プロトコール

参考文献

ab84855 has not yet been referenced specifically in any publications.

レビューと Q&A

There are currently no Customer reviews or Questions for ab84855.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

登録